

31st October, 2023

**The Secretary,
Bombay Stock Exchange
Ltd (BSE)**
Phiroze Jheejheebhoy
Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 543308
ISIN: INE967H01017

**The Secretary,
National Stock Exchange,**
Exchange Plaza,
5th Floor Plot No.C/1, 'G'
Block
Bandra - Kurla Complex
Mumbai - 400 051.
Symbol - KIMS
ISIN: INE967H01017

Dear Sir/ Madam

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update on the further acquisition of shares of M/s. SPANV Medisearch Lifesciences Private Limited

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Krishna Institute of Medical Sciences Limited (“the Company”) has made a further investment by acquiring an additional equity stake of 6.86% in M/s. SPANV Medisearch Lifesciences Private Limited, subsidiary Company. Consequently, the Company now holds 69.30% of the total paid-up Equity Share capital of M/s. SPANV Medisearch Lifesciences Private Limited.

We enclose herewith the details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/ CFD /CMD/4/2015 dated September 9, 2015 as Annexure to this letter.

The Company received information about the acquisition of an additional equity stake on Tuesday, 31.10.2023 @ 3:20 P.M.

Kindly take the above on your record. The same is also uploaded on the Company’s website at: <https://www.kimshospitals.com/investors/> > **Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015 > Intimations filed by the Company > Intimations under Regulation 30.**

We request you to kindly take the same on record.

Thanking You,

Yours truly

For Krishna Institute of Medical Sciences Limited

Umashankar Mantha
Company Secretary and Compliance Officer

ANNEXURE -1

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. IR/CFD/CMD/4/2015 dated September 9, 2015.

a	Name of the target entity, details in brief such as size, turnover, etc.,	<p>Name of the target entity: M/s. SPANV Medisearch Lifesciences Private Limited.</p> <p>M/s. SPANV Medisearch Lifesciences Private Limited (“KIMS Kingsway”) is a subsidiary of M/s. Krishna Institute of Medical Sciences Limited (“the Company/ KIMS”). KIMS has increased its holding from 62.44% to 69.30% (an increase of 6.86%) in KIMS Kingsway through a Secondary purchase.</p> <p>The total paid-up Equity Share Capital of KIMS Kingsway as of date is Rs. 1,74,86,251/- (Rupees One Crore Seventy Four Lakhs Eighty Six Thousand Two Hundred and Fifty One Only) and the Total Income of KIMS Kingsway for the Financial Year ended March 31, 2023, is Rs 1468.86 Million.</p>
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "arms length":	This is not a related party transaction. KIMS Kingsway is the existing subsidiary of KIMS and the transaction was done based on the valuation report.
c	Industry to which the entity being acquired belongs:	Healthcare Industry
d	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	KIMS being the Holding Company of KIMS Kingsway has made further investment in its subsidiary as a strategic investment.
e	Brief details of any governmental or regulatory approvals required for the acquisition:	The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013
f	Indicative time period for completion of the acquisition	Completed

g	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash
h	Cost of acquisition or the price at which the shares are acquired;	The Shares were acquired at Rs. 221.99 per equity share based on the valuation report and the total cost of acquisition is Rs. 26,63,88,000/-
i	Percentage of shareholding/control acquired and / or number of shares acquired;	KIMS has increased its holding from 62.44% to 69.30% (an increase of 6.86%) in KIMS Kingsway.
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Brief background about the entity acquired:</p> <p>“KIMS Kingsway” is one of the leading multi-specialty hospitals in Nagpur with a Bed capacity of 350 Beds. The top specialties of KIMS Kingsway include Cardiology, Nephrology, Urology, Orthopedics, Pediatrics, and Oncology.</p> <p>Date of Incorporation: 01/01/2018</p> <p>History of last 3 years Total Income - (Rs. in Millions)</p> <p>FY 23: Rs. 1468.86 FY 22: Rs. 1732.59 FY 21: Rs. 1103.00</p> <p>Presence: India</p> <p>Other Significant Information: please refer to the aforementioned.</p>